MONTREAL, April 3 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), the globalleader in cryotherapy products to treat cardiac arrhythmias, today announcedthat data on the Company's Arctic Front(R) catheter system to treat AtrialFibrillation (AFib) was presented at the 74th Annual Meeting of the GermanCardiac Society in Mannheim, Germany, March 27-29, 2008. CryoCath was wellrepresented at the meeting, with a record number of presentations oncryo-ablation. In total there were eight poster presentations and ten oralpresentations, including a standing room only cryo symposium from leadingelectrophysiologists that received 50 percent more attendance than theprevious year.
"This data, in line with previously reported results, bolsters ourconfidence that Arctic Front is rapidly becoming the standard of care forparoxysmal AFib," said Jan Keltjens, President and CEO of CryoCath. "What isexciting is the consistency these results represent. They are in line withresults from our STOP AF IDE feasibility studies and data presented atprevious scientific conferences and symposiums. It means Arctic Front is doingwhat it's supposed to do - provide a simple, anatomical based procedureresulting in safe and consistently efficacious outcomes."
About Arctic Front
Arctic Front is a minimally invasive cryo-balloon catheter designedspecifically to treat paroxysmal Atrial Fibrillation. This bi-directional,double balloon catheter enables physicians to rapidly isolate all fourpulmonary veins for the treatment of AFib. As of the end of December 2007, anestimated 2100 patients have been treated in 34 centers across Europe sinceapproval.
CryoCath - www.cryocath.com - is a medical technology company that leadsthe world in cryotherapy products to treat cardiac arrhythmias. With apriority focus on providing physicians with a complete solution of catheterproducts to treat cardiac arrhythmias, CryoCath has multiple products approvedin the U.S., across Europe and several ROW countries. The Company isdeveloping additional products to expand its pipeline of products to treatcardiac arrhythmias.
This press release includes "forward-looking statements" that are subjectto risks and uncertainties, including with respect to the timing of regulatorytrials and their outcome. For information identifying legislative orregulatory, economic, climatic, currency, technological, competitive and otherimportant factors that could cause actual results to differ materially fromthose anticipated in the forward looking statements, see CryoCath's annualreport available at www.sedar.com under the heading Risks and Uncertainties inthe Management's Discussion and Analysis section.Some of the highlights of the meeting include: - Data from a three centre AFib study on Arctic Front by Professor Dr. Schumacher from Herz- und GefaB-Klinik in Bad Neustadt, Germany, Dr. Pitschner from the Kerckhoff-Klinik in Bad Nauheim, Germany and Dr. Vogt from the Herz und Diabetes Zentrum NRW in Bad Oeynhausen, Germany. With a median follow-up time of 12 months, 74 percent of the 293 paroxysmal patients enrolled were AFib free after only one procedure and off anti-arrhythmic drugs (AADs). - Dr. Heintze, also from the Herz und Diabetes Zentrum NRW, presented follow up data on 168 patients treated in his center. This data includes patients from the three center AFib study listed above as well as a significant number of patients treated subsequently. The group of AFib sufferers was largely paroxysmal with approximately 7 percent persistent. After an average of 8.5 months follow up, 81 percent were AFib free and off drugs and more than 85 percent were considered a clinical success. - Data from all presentations collectively determined that with proper management of the procedure